Literature DB >> 20038207

Double-stranded RNA-activated protein kinase regulates early innate immune responses during respiratory syncytial virus infection.

Radiah A Corn Minor1, Gino V Limmon, Laura Miller-DeGraff, Darlene Dixon, Danica M K Andrews, Randal J Kaufman, Farhad Imani.   

Abstract

Respiratory syncytial virus (RSV) is the most common cause of childhood viral bronchiolitis and lung injury. Inflammatory responses significantly contribute to lung pathologies during RSV infections and bronchiolitis but the exact mechanisms have not been completely defined. The double-stranded RNA-activated protein kinase (PKR) functions to inhibit viral replication and participates in several signaling pathways associated with innate inflammatory immune responses. Using a functionally defective PKR (PKR(-/-)) mouse model, we investigated the role of this kinase in early events of RSV-induced inflammation. Our data showed that bronchoalveolar lavage (BAL) fluid from infected PKR(-/-) mice had significantly lower levels of several innate inflammatory cytokines and chemokines. Histological examinations revealed that there was less lung injury in infected PKR(-/-) mice as compared to the wild type. A genome-wide analysis showed that several early antiviral and immune regulatory genes were affected by PKR activation. These data suggest that PKR is a signaling molecule for immune responses during RSV infections.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20038207      PMCID: PMC3781957          DOI: 10.1089/jir.2009.0051

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  64 in total

1.  ERK-1/2 activity is required for efficient RSV infection.

Authors:  Xiaoyuan Kong; Homero San Juan; Aruna Behera; Mark E Peeples; Jerry Wu; Richard F Lockey; Shyam S Mohapatra
Journal:  FEBS Lett       Date:  2004-02-13       Impact factor: 4.124

2.  Interferon, double-stranded RNA, and protein phosphorylation.

Authors:  B Lebleu; G C Sen; S Shaila; B Cabrer; P Lengyel
Journal:  Proc Natl Acad Sci U S A       Date:  1976-09       Impact factor: 11.205

3.  The role of IFN in respiratory syncytial virus pathogenesis.

Authors:  Joan E Durbin; Teresa R Johnson; Russell K Durbin; Sara E Mertz; Rafaella A Morotti; R Stokes Peebles; Barney S Graham
Journal:  J Immunol       Date:  2002-03-15       Impact factor: 5.422

4.  Mechanism of interferon action: phosphorylation of protein synthesis initiation factor eIF-2 in interferon-treated human cells by a ribosome-associated kinase processing site specificity similar to hemin-regulated rabbit reticulocyte kinase.

Authors:  C E Samuel
Journal:  Proc Natl Acad Sci U S A       Date:  1979-02       Impact factor: 11.205

5.  Prolonged production of TNF-alpha exacerbates illness during respiratory syncytial virus infection.

Authors:  John A Rutigliano; Barney S Graham
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

6.  The immunologic response to infection with respiratory syncytial virus in infants.

Authors:  K McIntosh; H B Masters; I Orr; R K Chao; R M Barkin
Journal:  J Infect Dis       Date:  1978-07       Impact factor: 5.226

Review 7.  Pathogenesis of respiratory syncytial virus infection.

Authors:  Ralph A Tripp
Journal:  Viral Immunol       Date:  2004       Impact factor: 2.257

8.  The development of respiratory syncytial virus-specific IgE and the release of histamine in nasopharyngeal secretions after infection.

Authors:  R C Welliver; D T Wong; M Sun; E Middleton; R S Vaughan; P L Ogra
Journal:  N Engl J Med       Date:  1981-10-08       Impact factor: 91.245

9.  Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice.

Authors:  Hasan S Jafri; Susana Chavez-Bueno; Asuncion Mejias; Ana M Gomez; Ana M Rios; Shahryar S Nassi; Munira Yusuf; Payal Kapur; Robert D Hardy; Jeanine Hatfield; Beverly B Rogers; Karen Krisher; Octavio Ramilo
Journal:  J Infect Dis       Date:  2004-04-29       Impact factor: 5.226

10.  Respiratory syncytial virus infections in infants: quantitation and duration of shedding.

Authors:  C B Hall; R G Douglas; J M Geiman
Journal:  J Pediatr       Date:  1976-07       Impact factor: 4.406

View more
  6 in total

1.  Inosine-containing RNA is a novel innate immune recognition element and reduces RSV infection.

Authors:  Jie-ying Liao; Sheetal A Thakur; Zachary B Zalinger; Kevin E Gerrish; Farhad Imani
Journal:  PLoS One       Date:  2011-10-18       Impact factor: 3.240

2.  Activation of protein kinase R is required for induction of stress granules by respiratory syncytial virus but dispensable for viral replication.

Authors:  Michael E Lindquist; Bernardo A Mainou; Terence S Dermody; James E Crowe
Journal:  Virology       Date:  2011-03-05       Impact factor: 3.616

3.  A chemokine gene expression signature derived from meta-analysis predicts the pathogenicity of viral respiratory infections.

Authors:  Stewart T Chang; Nicolas Tchitchek; Debashis Ghosh; Arndt Benecke; Michael G Katze
Journal:  BMC Syst Biol       Date:  2011-12-22

Review 4.  How RSV Proteins Join Forces to Overcome the Host Innate Immune Response.

Authors:  Tessa Van Royen; Iebe Rossey; Koen Sedeyn; Bert Schepens; Xavier Saelens
Journal:  Viruses       Date:  2022-02-17       Impact factor: 5.048

5.  Mumps Virus Induces Protein-Kinase-R-Dependent Stress Granules, Partly Suppressing Type III Interferon Production.

Authors:  Shin Hashimoto; Soh Yamamoto; Noriko Ogasawara; Toyotaka Sato; Keisuke Yamamoto; Hiroshi Katoh; Toru Kubota; Tsukasa Shiraishi; Takashi Kojima; Tetsuo Himi; Hiroyuki Tsutsumi; Shin-Ichi Yokota
Journal:  PLoS One       Date:  2016-08-25       Impact factor: 3.240

6.  Alveolar Macrophages Can Control Respiratory Syncytial Virus Infection in the Absence of Type I Interferons.

Authors:  Spyridon Makris; Monika Bajorek; Fiona J Culley; Michelle Goritzka; Cecilia Johansson
Journal:  J Innate Immun       Date:  2016-07-16       Impact factor: 7.349

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.